THE PHARMACEUTICAL MARKET: BANGLADESH - REVIEW
Politically, Prime Minister Hasina’s government has stabilised the country. Economically, real growth is projected to be moderate in the forecast period. However, per capita expenditure remains the lowest rate in the Asia Pacific region covered by Espicom. Legally, as Bangladesh is a developing country, it does not have to abide by the WTO’s TRIPS agreement until 2016, an aspect that is being exploited by the local generic sector. Demographically, Bangladesh will be the fifth most populated country in the Asia Pacific region by 2016. However, the country still has an extremely high infant mortality rate.
Bangladesh is a very poor country and the majority of the population cannot afford to see health professionals when they fall ill. As a result, there has been a long tradition of self-medication in the country, which has led to the misuse of drugs, particularly drugs that are normally prescription-only. The Bangladeshi pharmaceutical distribution network tends to be more retail-orientated and the bulk of distribution is done by the companies themselves. An anarchic situation prevails in the marketing and sales of drugs, due to a large number of illegal and unlicensed drug stores selling poorly-manufactured pharmaceuticals.
The Bangladeshi pharmaceutical market is projected to grow at a high single-digit CAGR in US dollar terms during the forecast period. Bangladesh will have the smallest pharmaceutical market in the Asia Pacific region covered by Espicom in 2016. The balance of pharmaceutical trade remains negative, with the deficit largely accountable to imports of raw materials and antisera & vaccines. There is a large generic sector in Bangladesh, led by companies such as Square and Beximco. However, despite the country possessing huge manufacturing capabilities that supply around 96% of domestic need, the complete lack of R&D by local manufacturers could affect the market.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included
Pharmaceutical Market Bangladesh
Published: February 2012 No. of Pages: 54 Price: US $ 1085
Politically, Prime Minister Hasina’s government has stabilised the country. Economically, real growth is projected to be moderate in the forecast period. However, per capita expenditure remains the lowest rate in the Asia Pacific region covered by Espicom. Legally, as Bangladesh is a developing country, it does not have to abide by the WTO’s TRIPS agreement until 2016, an aspect that is being exploited by the local generic sector. Demographically, Bangladesh will be the fifth most populated country in the Asia Pacific region by 2016. However, the country still has an extremely high infant mortality rate.
Bangladesh is a very poor country and the majority of the population cannot afford to see health professionals when they fall ill. As a result, there has been a long tradition of self-medication in the country, which has led to the misuse of drugs, particularly drugs that are normally prescription-only. The Bangladeshi pharmaceutical distribution network tends to be more retail-orientated and the bulk of distribution is done by the companies themselves. An anarchic situation prevails in the marketing and sales of drugs, due to a large number of illegal and unlicensed drug stores selling poorly-manufactured pharmaceuticals.
The Bangladeshi pharmaceutical market is projected to grow at a high single-digit CAGR in US dollar terms during the forecast period. Bangladesh will have the smallest pharmaceutical market in the Asia Pacific region covered by Espicom in 2016. The balance of pharmaceutical trade remains negative, with the deficit largely accountable to imports of raw materials and antisera & vaccines. There is a large generic sector in Bangladesh, led by companies such as Square and Beximco. However, despite the country possessing huge manufacturing capabilities that supply around 96% of domestic need, the complete lack of R&D by local manufacturers could affect the market.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included
Pharmaceutical Market Bangladesh
Published: February 2012 No. of Pages: 54 Price: US $ 1085
Table Of Contents
EXECUTIVE SUMMARY 1Snapshot: Strategic Espicom Analysis2
Snapshot: Key Data Projections3
MACROENVIRONMENT 4POLITICAL4
ECONOMIC5
Projections5
LEGAL6
DEMOGRAPHIC7
Projections7
Demographic Indicators8
Births 8
Deaths 8
Infant Deaths 8
Life Expectancy at Birth 8
EPIDEMIOLOGY 9DISEASE BURDEN9
Leading Causes of Mortality9
DISEASE PREVALENCE10
Communicable Diseases10
Bangladesh Introduces Combination Vaccine to Childhood Immunisation Programme 10
Non-Communicable Diseases11
HIV/AIDS 11
Tuberculosis 11
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 12ORGANISATION12
EXPENDITURE12
Projections12
Latest Figures13
INFRASTRUCTURE14
Inpatient Infrastructure14
Outpatient Infrastructure14
WORKFORCE15
Projections15
Current State16
REGULATORY AFFAIRS 17INTERNATIONAL AUTHORITY17
Commonwealth Pharmacists Association17
International Pharmaceutical Federation17
NATIONAL AUTHORITY18
National Drug Policy18
REGULATORY DEVELOPMENTS19
MARKETING REGISTRATION19
PROMOTION19
Advertising19
PRICING & REIMBURSEMENT 20
DISTRIBUTION CHANNELS 21DRUG WHOLESALING21
Leading Wholesalers21
Zuellig Pharma 21
Wholesaler Developments21
DRUG RETAILING21
MARKET ANALYSIS 22SIZE 22
Projections22
Historical Figures24
PRODUCT DEVELOPMENT 25
MANUFACTURING 25
TRADE27
Exports27
Imports30
Balance of Trade34
COMPETITION 35TRADE ASSOCIATION35
Bangladesh Association of Pharmaceutical Industries (BAPI) 35
TRADE FAIRS35
Pharma Bangladesh Expo35
COMPANY INTELLIGENCE 36
Domestic Manufacturers36
Advanced Chemical Industries (ACI)36
Aristopharma36
Beacon36
Eskayef Bangladesh 37
Drug International 37
General Pharmaceuticals 37
Incepta Pharmaceuticals 37
Medimet Pharmaceuticals 37
Ospinin 37
Renata 37
Multinational Manufacturers38
Bayer38
Novartis38
sanofi-aventis38
Sun Pharmaceutical (Bangladesh)38
Competitive Strategies38
OTC PHARMACEUTICALS 39MARKET SIZE39
GENERIC PHARMACEUTICALS40MARKET SIZE 40
COMPETITION 40
Company Intelligence40
ACME Group40
Beximco Pharmaceuticals 41
Square Pharmaceuticals 44
Zenith Pharmaceuticals 44
Competitive Strategies 44
BIOLOGICS & BIOSIMILARS 45COMPETITION 45
Company Intelligence45
Biopharma 45
Sandoz Bangladesh45
Square Pharmaceuticals45
CONCLUSIONS: OPPORTUNITIES & CHALLENGES46Strategic Espicom Analysis 46
MACROENVIRONMENT46
EPIDEMIOLOGY46
HEALTHCARE47
REGULATORY AFFAIRS47
PRICING & REIMBURSEMENT48
DISTRIBUTION CHANNELS48
MARKET48
COMPETITION 49
OTC PHARMACEUTICALS49
GENERIC PHARMACEUTICALS49
BIOLOGICS & BIOSIMILARS50
Radar Analysis52
SWOT Analysis52
DIRECTORY 53GOVERNMENT ORGANISATIONS53
PHARMACEUTICAL COMPANIES53
Domestic Companies53
Multinational Companies53
TRADE ORGANISATIONS53
List of Tables
List of Charts
EXECUTIVE SUMMARY 1Snapshot: Strategic Espicom Analysis2
Snapshot: Key Data Projections3
MACROENVIRONMENT 4POLITICAL4
ECONOMIC5
Projections5
LEGAL6
DEMOGRAPHIC7
Projections7
Demographic Indicators8
Births 8
Deaths 8
Infant Deaths 8
Life Expectancy at Birth 8
EPIDEMIOLOGY 9DISEASE BURDEN9
Leading Causes of Mortality9
DISEASE PREVALENCE10
Communicable Diseases10
Bangladesh Introduces Combination Vaccine to Childhood Immunisation Programme 10
Non-Communicable Diseases11
HIV/AIDS 11
Tuberculosis 11
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS 12ORGANISATION12
EXPENDITURE12
Projections12
Latest Figures13
INFRASTRUCTURE14
Inpatient Infrastructure14
Outpatient Infrastructure14
WORKFORCE15
Projections15
Current State16
REGULATORY AFFAIRS 17INTERNATIONAL AUTHORITY17
Commonwealth Pharmacists Association17
International Pharmaceutical Federation17
NATIONAL AUTHORITY18
National Drug Policy18
REGULATORY DEVELOPMENTS19
MARKETING REGISTRATION19
PROMOTION19
Advertising19
PRICING & REIMBURSEMENT 20
DISTRIBUTION CHANNELS 21DRUG WHOLESALING21
Leading Wholesalers21
Zuellig Pharma 21
Wholesaler Developments21
DRUG RETAILING21
MARKET ANALYSIS 22SIZE 22
Projections22
Historical Figures24
PRODUCT DEVELOPMENT 25
MANUFACTURING 25
TRADE27
Exports27
Imports30
Balance of Trade34
COMPETITION 35TRADE ASSOCIATION35
Bangladesh Association of Pharmaceutical Industries (BAPI) 35
TRADE FAIRS35
Pharma Bangladesh Expo35
COMPANY INTELLIGENCE 36
Domestic Manufacturers36
Advanced Chemical Industries (ACI)36
Aristopharma36
Beacon36
Eskayef Bangladesh 37
Drug International 37
General Pharmaceuticals 37
Incepta Pharmaceuticals 37
Medimet Pharmaceuticals 37
Ospinin 37
Renata 37
Multinational Manufacturers38
Bayer38
Novartis38
sanofi-aventis38
Sun Pharmaceutical (Bangladesh)38
Competitive Strategies38
OTC PHARMACEUTICALS 39MARKET SIZE39
GENERIC PHARMACEUTICALS40MARKET SIZE 40
COMPETITION 40
Company Intelligence40
ACME Group40
Beximco Pharmaceuticals 41
Square Pharmaceuticals 44
Zenith Pharmaceuticals 44
Competitive Strategies 44
BIOLOGICS & BIOSIMILARS 45COMPETITION 45
Company Intelligence45
Biopharma 45
Sandoz Bangladesh45
Square Pharmaceuticals45
CONCLUSIONS: OPPORTUNITIES & CHALLENGES46Strategic Espicom Analysis 46
MACROENVIRONMENT46
EPIDEMIOLOGY46
HEALTHCARE47
REGULATORY AFFAIRS47
PRICING & REIMBURSEMENT48
DISTRIBUTION CHANNELS48
MARKET48
COMPETITION 49
OTC PHARMACEUTICALS49
GENERIC PHARMACEUTICALS49
BIOLOGICS & BIOSIMILARS50
Radar Analysis52
SWOT Analysis52
DIRECTORY 53GOVERNMENT ORGANISATIONS53
PHARMACEUTICAL COMPANIES53
Domestic Companies53
Multinational Companies53
TRADE ORGANISATIONS53
List of Tables
List of Charts
No comments:
Post a Comment